CDK6 and cancer: We also identified cyclin-dependent kinase-6 (CDK6) showing overexpression across cancer types, primarily overexpressed in MB (24%), HCC (23%), BRCA (17%), and PRAD (16%) cases (FDR ≤ 0.026).